Bragar Eagel & Squire, P.C. Urges Agilon, Soleno, Avita, and Coty Investors to Reach Out About Current Investigations
Agilon Health Investigation: Bragar Eagel & Squire, P.C. is investigating Agilon Health for potential violations of federal securities laws following the unexpected resignation of its CEO and the withdrawal of its earnings guidance, which led to a significant drop in share price.
Soleno Therapeutics Report: The law firm is also looking into Soleno Therapeutics after a report from Scorpion Capital criticized its product, Vykat XR, as overpriced and unsafe, resulting in a notable decline in the company's stock price.
AVITA Medical Claims Backlog: AVITA Medical is under investigation due to a reported backlog of unpaid claims for its Recell procedures, which negatively impacted its financial results and led to a sharp decrease in share price.
Coty's Financial Losses: Coty, Inc. is facing scrutiny after reporting an unexpected financial loss and disappointing guidance, attributed to broader market challenges, which caused its stock price to fall significantly.
Trade with 70% Backtested Accuracy
Analyst Views on AGL
About AGL
About the author

- Class Action Notice: Rosen Law Firm reminds investors who purchased Agilon Health (NYSE:AGL) securities between February 26 and August 4, 2025, that they must apply to be lead plaintiff by March 2, 2026, or risk losing the opportunity to represent other investors in the class action lawsuit.
- Fee Arrangement: Investors participating in the class action will incur no upfront costs, as the law firm operates on a contingency fee basis, allowing investors to seek compensation without financial burden, thereby lowering the barrier to litigation participation.
- Lawsuit Background: The lawsuit alleges that Agilon Health made misleading financial guidance during the class period, resulting in investor losses when the true details emerged, indicating that the company failed to accurately reflect its financial health amidst industry challenges, which could impact future market trust.
- Law Firm Advantage: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling similar cases, which investors should consider when selecting legal counsel.
- Class Action Notice: Rosen Law Firm reminds investors who purchased Agilon Health (NYSE: AGL) securities between February 26, 2025, and August 4, 2025, that they must apply to be lead plaintiff by March 2, 2026, to represent other investors in the class action lawsuit.
- Fee Arrangement: Investors can participate in the class action without any upfront costs, as the law firm operates on a contingency fee basis, which alleviates the financial burden on investors until compensation is secured.
- Lawsuit Background: The lawsuit alleges that Agilon Health made false or misleading statements during the class period, resulting in investor losses when the true situation was revealed, indicating significant misjudgments in the company's financial outlook that could affect future market trust.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and experience in handling similar cases, which investors should consider when selecting legal counsel.
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential securities fraud claims against agilon health related to securities transactions between February 26, 2025, and August 4, 2025, urging investors to contact them before the March 2, 2026, deadline to seek lead plaintiff status.
- Earnings Warning Impact: agilon health's August 4, 2025, earnings report revealed a decision to suspend its previously issued financial guidance for 2025 due to worsening industry headwinds, resulting in a 51.5% stock price drop the following day, indicating severe market concerns about the company's outlook.
- False Statement Allegations: The lawsuit alleges that agilon health and its executives recklessly issued guidance they knew was unattainable and failed to disclose significant industry challenges, leading to investor losses and highlighting serious deficiencies in corporate governance and transparency.
- Investor Rights Protection: Faruq & Faruqi encourages anyone with information, including former employees and shareholders, to come forward to support the investigation, emphasizing the importance of protecting investor rights and providing legal support for affected investors.
- SLM Corporation Lawsuit: SLM Corporation (NASDAQ:SLM) is facing allegations for failing to disclose a significant rise in early-stage delinquencies during the class period from July 25 to August 14, 2025, misleading investors about the company's business stability, with a lead plaintiff deadline of February 17, 2026.
- Klarna Group Allegations: Klarna Group plc (NYSE:KLAR) is accused of materially understating the risks associated with its loss reserves during its September 2025 IPO, leading to misleading positive statements about its business prospects, with a lead plaintiff deadline of February 20, 2026.
- agilon Health Issues: agilon health, inc. (NYSE:AGL) is under scrutiny for issuing unrealistic guidance for 2025 amid known industry headwinds, misleading investors about the financial impact of its strategic actions, with a lead plaintiff deadline of March 2, 2026.
- Fermi Inc. Lawsuit: Fermi Inc. (NASDAQ:FRMI) faces allegations of overstating tenant demand for its Project Matador and failing to disclose reliance on a single tenant's funding, misleading investors about its business outlook, with a lead plaintiff deadline of March 6, 2026.
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Agilon Health, seeking damages for investors who purchased securities between February 26, 2025, and August 4, 2025, highlighting serious concerns over the company's financial transparency.
- False Statement Allegations: The complaint alleges that the defendants made false and misleading statements throughout the class period, particularly regarding their 2026 performance guidance, indicating a failure to disclose financial realities amidst industry challenges, which could lead to significant investor losses.
- Investor Actions: Affected investors are encouraged to apply to be lead plaintiffs by March 2, 2026, to share in any potential recovery from the lawsuit, underscoring the importance of legal proceedings in protecting investor rights.
- Law Firm's Strength: Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm specializing in securities fraud class actions, having recovered hundreds of millions for investors, demonstrating its expertise in upholding market integrity.
- Leadership Transition: Agilon Health announced the resignation of CEO Steven Sell and withdrew its full-year 2025 earnings guidance in its Q2 2025 earnings report, indicating instability in management that could undermine investor confidence.
- Stock Price Plunge: Following the release of this news, Agilon's shares fell over 27% in after-hours trading, reflecting market concerns about the company's future performance and potentially leading to significant losses for investors.
- Legal Investigation Initiated: DJS Law Group is investigating whether Agilon made misleading statements or failed to disclose information pertinent to investors, which could expose the company to legal liabilities and further exacerbate investor anxiety.
- Investor Rights Protection: DJS Law Group focuses on enhancing investor returns through balanced counseling and aggressive advocacy, indicating its commitment to providing legal support for affected investors, potentially leading to compensation opportunities.







